Back to News
Market Impact: 0.22
NAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMed
Source: PR Newswire
Healthcare & BiotechArtificial IntelligencePrivate Markets & VentureTechnology & Innovation
ImpriMed, which combines ex vivo functional testing with multimodal AI to support personalized cancer-treatment decisions and drug development, received an investment from NAVER D2SF. The funding is part of ImpriMed's $10 million Series A2 bridge round and will support U.S. commercialization and expansion into Asia. The investment is positive for the company's growth prospects but is unlikely to have broad public-market impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
More News
- Marvell, Lumentum tout historic $115B deal to create ‘category leader' in AI connectivity
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- New Apple CEO John Ternus chalks up some early wins, but the honeymoon is over
- Anthropic releases amended IPO prospectus with third-quarter financials
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Oracle files to sell $20 billion in new stock, bonds to finance AI buildout